Machine Learning

A new five-year deal will leverage patient-derived stem cells and AI to revolutionize the hunt for Alzheimer's cures, aiming to bridge a critical gap.

A new partnership aims to manufacture a life-saving gene therapy for NKH, a devastating rare disorder, driven by a family's relentless advocacy.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

An Indiana firm's implantable pump gains key FDA status, promising a future with less mental burden for Type 1 Diabetes patients. But the road is long.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

eToro reports a record $868M in 2025 net contribution and adds $100M to its buyback, betting on AI and its super-app vision despite a Q4 crypto lull.

Digital engineering firm Simform invests $3M to scale its Microsoft AI practice, aiming to capture market share with proprietary IP and a co-sell strategy.

Ascend Elements' award to TDK Ventures reveals a new VC model, where hands-on partnership is key to building a secure, circular battery supply chain.

Tech giant Sony secures access to crucial 5G, Wi-Fi, and video patents, renewing a long-standing agreement with R&D powerhouse InterDigital.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

Allocate's 350% asset growth signals a major shift as wealth advisors embrace private markets. Discover how its AI-powered platform is making it possible.

New long-term data shows duvakitug maintained remission in IBD patients for nearly a year, positioning it as a top contender in a new class of therapy.

A second real-world study finds an FDA-approved device brings significant relief to over 80% of tinnitus patients, offering new hope for millions.